Cycliq Group Ltd

CYQ

Cycliq Group Ltd. engages in the manufacture of electronic safety accessories for cyclists. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2007-11-21. The company operates predominantly in the technology industry, manufacturing high-definition bike cameras and safety lights. The company has operations in Australia and China, with direct-to-consumer sales from its Website and Amazon, and access to more than 6,000 retail points of presence through a network of regional distributors and retail partners in the United States, United Kingdom, European Union (EU) and Asia-Pacific. The firm provides various accessories, including Duo Mount, Saddle Rail Mount, Fly6 - Rear Pannier Mount Pack, Fly12 - Handlebar Mount, Universal Adapter Pack, Cycliq Security Tag Holder, Microphone Filters and Fly6 Gen 3 Silicone Case. The company also offers lumiere unisex reflective jackets. Its subsidiaries include Cycliq Products Pty Ltd and Cycliq Research and Development (HK) Ltd.

Corazon Mining Limited

CZN

Corazon Mining Ltd. is an exploration company, which engages in the exploration of nickel, cobalt, copper and gold. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-06-30. The firm is an explorer advancing the Lynn Lake Nickel-Copper-Cobalt Sulfide Project in Manitoba, Canada, as well as the Mt Gilmore cobalt-copper-gold (Mt Gilmore) and Miriam nickel Sulfide projects (Miriam) in Australia. The Lynn Lake Nickel-Copper-Cobalt Sulfide Project is a significant Class-1 nickel resource. The Mt Gilmore Project is located 35 kilometers from the city of Grafton in north-eastern New South Wales. The firm owns an 80% interest in Mt Gilmore. Mt Gilmore is focused on multiple rare, cobalt-rich sulfide deposits, similar to Cobalt Ridge. The Miriam comprises five Prospecting License applications (P15/6135 to P15/6139 inclusive) and is located approximately 10 kilometers south-southwest of Coolgardie on an ultramafic trend, which hosts Auroch Minerals’ Miriam and Nepean Nickel Deposits.

Cyprium Metals Limited

CYM

Cyprium Metals Ltd. engages in the exploration of gold and copper deposits in Indonesia. The company is headquartered in Subiaco, Western Australia. The Company’s flagship property is the Nifty Copper Mine in Western Australia, which produces copper from both oxide and sulfide resources. The Nifty Copper Mine is located on the western edge of the Great Sandy Desert in the north-eastern Pilbara region of Western Australia, approximately 350 kilometers (km) southeast of Port Hedland. Its other assets include copper-focused properties in the Paterson and Murchison Provinces, including multiple defined resources. Its Maroochydore deposit is located in the north-eastern Pilbara region of Western Australia, approximately 85km southeast of Nifty. Paterson Exploration Project is located in the north-eastern Pilbara region of Western Australia and covers over 2,400 km2 land package. The Murchison Copper Gold Project, comprising the Cue and Nanadie Well Copper Projects, is in the eastern Murchison region of Western Australia, over 20km east of Cue and 75km southeast of Meekatharra.

Cynata Therapeutics Limited

CYP

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.